Ionis Pharmaceuticals, Inc.
IONS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $705 | $788 | $587 | $810 |
| % Growth | -10.5% | 34.1% | -27.5% | – |
| Cost of Goods Sold | $11 | $9 | $14 | $11 |
| Gross Profit | $694 | $779 | $573 | $800 |
| % Margin | 98.4% | 98.8% | 97.6% | 98.7% |
| R&D Expenses | $902 | $900 | $833 | $643 |
| G&A Expenses | $268 | $233 | $150 | $171 |
| SG&A Expenses | $268 | $233 | $150 | $171 |
| Sales & Mktg Exp. | $0 | $0 | -$0 | $0 |
| Other Operating Expenses | -$0 | $0 | $0 | $16 |
| Operating Expenses | $1,169 | $1,132 | $983 | $830 |
| Operating Income | -$475 | -$354 | -$410 | -$30 |
| % Margin | -67.4% | -44.9% | -69.8% | -3.7% |
| Other Income/Exp. Net | $15 | $20 | $152 | $1 |
| Pre-Tax Income | -$460 | -$334 | -$258 | -$29 |
| Tax Expense | -$6 | $32 | $12 | -$1 |
| Net Income | -$454 | -$366 | -$270 | -$29 |
| % Margin | -64.4% | -46.5% | -45.9% | -3.5% |
| EPS | -3.04 | -2.56 | -1.9 | -0.2 |
| % Growth | -18.8% | -34.7% | -850% | – |
| EPS Diluted | -3.04 | -2.56 | -1.9 | -0.2 |
| Weighted Avg Shares Out | 150 | 143 | 142 | 141 |
| Weighted Avg Shares Out Dil | 150 | 143 | 142 | 141 |
| Supplemental Information | – | – | – | – |
| Interest Income | $107 | $89 | $25 | $10 |
| Interest Expense | $90 | $81 | $8 | $9 |
| Depreciation & Amortization | $22 | $22 | $22 | $20 |
| EBITDA | -$354 | -$236 | -$228 | -$5 |
| % Margin | -50.2% | -29.9% | -38.8% | -0.6% |